Edition:
United Kingdom

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

226.39USD
18 Apr 2019
Change (% chg)

$-0.79 (-0.35%)
Prev Close
$227.18
Open
$227.28
Day's High
$227.88
Day's Low
$221.53
Volume
2,760,973
Avg. Vol
1,984,456
52-wk High
$388.67
52-wk Low
$216.12

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 21.50 29.30 32.55
EPS (TTM): 15.23 -- --
ROI: 17.59 14.23 13.83
ROE: 28.64 15.46 15.25

Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

ZURICH Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.

03 Apr 2019

Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group

ZURICH, April 3 Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.

03 Apr 2019

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion (3.8 billion pounds), days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

25 Mar 2019

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

25 Mar 2019

Biogen announces $5 bln buyback days after shelving Alzheimer's trials

March 25 Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

25 Mar 2019

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

22 Mar 2019

UPDATE 2-Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

* Eisai begins BAN2401 trials, confident in amyloid beta target

22 Mar 2019

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion (£13.8 billion) of its value on Thursday. | Video

21 Mar 2019

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. | Video

21 Mar 2019

UPDATE 5-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

CHICAGO/TOKYO, March 21 Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

21 Mar 2019

Earnings vs. Estimates